ADVFN Logo ADVFN

Wir konnten keine Ergebnisse für:
Stelle sicher, dass deine Schreibweise korrekt ist oder versuche deine Suche zu erweitern.

Trends

Toplisten

Es scheint, dass du nicht eingeloggt bist.
Klicke auf den Button unten, um dich einzuloggen und deine zuletzt angesehenen Aktien zu sehen.

Registrieren

Bereits Mitglied? Einloggen

Pepperstone

Jetzt Handeln

Pepperstone
Marktdaten
News
Werkzeuge
Märkte
Entdecken

Hot Features

Follow Feed

Vernetzen Sie sich mit Händlern und Investoren in unserer Follow-Feed-Community.

Optionen-Flow

Erkunden Sie umfassende Optionsdaten und nutzen Sie erweiterte Filter mit Options Flow.

Watchlist

Organisieren und überwachen Sie Ihre Aktien- und Vermögensbeobachtungsliste mit dem Monitor.
Anmelden Premium IconPremium Help Menu
DAX
18.001,60
0,54%
S&P 500
5.127,79
1,26%
Dow Jones
38.675,68
1,18%
Euro vs US Dollar
1,07624
-0,09%
Bitcoin
63.960,01
0,11%
Registration Strip Icon for monitor Überwachen Sie mehrere Echtzeitkurse von führenden Börsen wie NASDAQ, NYSE, AMEX, Bovespa und mehr.
Registrieren
  1. Startseite
  2. Investieren
  3. Aktien
  4. USA
  5. NASDAQ
  6. GeoVax Labs Inc (GOVX)

  7. GeoVax Labs Inc (GOVX) News

GOVX GeoVax Labs Inc

1,61
0,19 (13,38%)
04 Mai 2024 - Geschlossen
Verzögert um 15 Minuten
Name Symbol Markt Aktientyp
GeoVax Labs Inc GOVX NASDAQ Common Stock
  Änderung Änderung % Aktuell Zeit
Upgrade Icon
0,19 13,38% 1,61 06:00:05
Handelsbeginn Niedrig Hoch Schlusskurs Handelsende
1,42 1,42 1,70 1,61 1,42
more quote information »

Aktuelle News

Datum Zeit Quelle Überschrift
04.4.202418:30GLOBEGeoVax Presents Data on GEO-CM04S1, a Next Generation..
28.3.202414:00GLOBEGeoVax to Present Data on GEO-CM04S1, a Next Generation..
12.3.202414:00GLOBEGeoVax to Present at the 36th Annual Roth Conference
11.3.202421:13EDGAR2Form 10-K/A - Annual report [Section 13 and 15(d), not S-K..
11.3.202405:15EDGAR2Form EFFECT - Notice of Effectiveness
06.3.202415:00GLOBEGeoVax Achieves Milestone in Transition to Commercially..
01.3.202422:08EDGAR2Form S-3 - Registration statement under Securities Act of..
29.2.202422:05EDGAR2Form 10-K - Annual report [Section 13 and 15(d), not S-K..
29.2.202422:00GLOBEGeoVax Reports 2023 Year-End Financial Results and Provides..
22.2.202422:41EDGAR2Form 4 - Statement of changes in beneficial ownership of..
22.2.202415:00GLOBEGeoVax to Report 2023 Financial Results and Provide..
19.2.202415:00GLOBEGeoVax to Present at the 2024 BIO CEO & Investor Conference
16.2.202422:01EDGAR2Form 8-K - Current report
14.2.202421:38EDGAR2Form SC 13G - Statement of acquisition of beneficial..
13.2.202415:00GLOBEGeoVax Announces Multiple Patent Issuances and Allowances
07.2.202422:43EDGAR2Form 4 - Statement of changes in beneficial ownership of..
06.2.202415:00GLOBEGeoVax Reports Positive Interim Data From Phase 2 Clinical..
31.1.202419:13EDGAR2Form 8-K - Current report
29.1.202415:00GLOBEGeoVax Announces 1-for-15 Reverse Stock Split to Regain..
16.1.202422:03EDGAR2Form 8-K - Current report
12.1.202422:00EDGAR2Form 424B3 - Prospectus [Rule 424(b)(3)]
08.1.202415:00GLOBEGeoVax Appoints Dr. Marc Pipas as Executive Medical..
04.1.202415:00GLOBEGeoVax Announces Gedeptin® Patient Enrollment Closure for..
03.1.202415:00GLOBEGeoVax Announces Issuance of Malaria Vaccine Patent
02.1.202422:10EDGAR2Form S-1 - General form for registration of securities under..
27.12.202315:00GLOBEGeoVax to Present at Biotech Showcase During J.P. Morgan..
26.12.202321:51EDGAR2Form 4 - Statement of changes in beneficial ownership of..
19.12.202315:00GLOBEGeoVax Expands Rights Under NIH COVID-19 License to Include..
08.12.202322:02EDGAR2Form 8-K - Current report
04.12.202314:00EDGAR2Form 8-K - Current report
30.11.202322:30GLOBEGeoVax Hemorrhagic Fever Vaccine Data Presented at World..
29.11.202315:00GLOBEGeoVax to Participate in Upcoming December Investor Events
28.11.202315:00GLOBEGeoVax COVID-19 Vaccine Clinical Data Presented at World..
27.11.202322:06EDGAR2Form DEF 14A - Other definitive proxy statements
17.11.202322:27EDGAR2Form PRE 14A - Other preliminary proxy statements
14.11.202315:00GLOBEProgress on GeoVax’s Universal Coronavirus Vaccine..
09.11.202318:40EDGAR2Form 8-K - Current report
08.11.202322:04EDGAR2Form 424B3 - Prospectus [Rule 424(b)(3)]
08.11.202322:03EDGAR2Form 424B3 - Prospectus [Rule 424(b)(3)]
08.11.202322:01EDGAR2Form 424B3 - Prospectus [Rule 424(b)(3)]
08.11.202322:00EDGAR2Form 10-Q - Quarterly report [Sections 13 or 15(d)]
08.11.202322:00GLOBEGeoVax Reports Third Quarter 2023 Financial Results and..
31.10.202314:00GLOBEGeoVax to Report Third Quarter 2023 Financial Results and..
30.10.202314:00GLOBEGeoVax Commences Site Expansion for Phase 2 Trial of..
25.10.202315:00GLOBEGeoVax to Participate in Upcoming November Investor and..
24.10.202315:00GLOBEGeoVax Update: Clinical and Operational Progress Toward..
09.10.202315:00GLOBEGeoVax Receives Notice of Allowance for Marburg Vaccine..
05.10.202315:00GLOBEGeoVax Receives Notice of Allowance for HIV Vaccine Patent
27.9.202322:33EDGAR2Form 4 - Statement of changes in beneficial ownership of..
27.9.202315:00GLOBEGeoVax to Participate in Upcoming October Investor and..

Kürzlich von Ihnen besucht

NASDAQ
GOVX
GeoVax Labs
Delayed Upgrade Clock
ADVFN Logo

Deutschland
Unternehmen
Geschäft
Popular
App herunterladen

Support: +44 (0) 203 8794 460 | support@advfn.de

Durch das Benutzen des ADVFN Angebotes akzeptieren Sie folgende Allgemeine Geschäftsbedingungen

© 2024 ADVFN PLC - Alle Rechte vorbehalten